The FDA gained input from bio/pharma companies, CDMOs/CMOs, & others on its proposed Quality Metrics Reporting Program, which will gather info from manufacturers and be used by the FDA in its quality surveillance activities....
[Patricia Van Arnum, DCAT Editorial Director]
